AZP-3813 is macrocyclic peptide growth hormone (GH) receptor antagonist for the treatment of acromegaly that is undergoing pre-investigational new drug activities.

Acromegaly is a rare disease characterized by abnormally high levels of GH, which in turn causes excess production of insulin-like growth factor-1 (IGF-1). By preventing the interaction between GH and its receptor, AZP-3813 is expected to normalize the excess IGF-1 and control symptoms in patients with acromegaly.

AZP-3813 has been selected out of more than 140 optimized peptides for its superior pharmacokinetic and pharmacodynamic properties that combined make it highly effective in preventing GH from interacting with its receptor.

AZP-3813 Acromegal
Scroll to Top